Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A randomized, placebo-controlled, and observer-blinded Phase IIb, multi-center clinical study of BPZE1 versus Boostrix

Trial Profile

A randomized, placebo-controlled, and observer-blinded Phase IIb, multi-center clinical study of BPZE1 versus Boostrix

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 19 Nov 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs BPZE 1 (Primary) ; DTaP vaccine
  • Indications Pertussis
  • Focus Adverse reactions; Pharmacodynamics
  • Sponsors ILiAD Biotechnologies
  • Most Recent Events

    • 19 Nov 2019 According to an ILiAD Biotechnologies media release, Cheryl Keech, M.D., Ph.D played an a pivotal role in advising the company and designing of this study.
    • 08 Oct 2019 According to an ILiAD Biotechnologies media release, results from this study are expected at the end of Q1 2020.
    • 08 Oct 2019 Status changed from recruiting to active, no longer recruiting, according to an ILiAD Biotechnologies media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top